BGP-21172

BGP-21172 is a novel small molecule that acts as a potent and selective agonist of the Sigma-1 receptor. Developed by Egis Pharmaceuticals, the compound has been primarily investigated in preclinical research for its potential in treating cognitive deficits and psychiatric disorders. The Sigma-1 receptor is an endoplasmic reticulum-resident chaperone protein that plays a crucial role in modulating calcium signaling, protein folding, and neurotransmitter release. By activating this receptor, BGP-21172 enhances cholinergic transmission and exerts anti-apoptotic and neuroprotective effects. Preclinical studies have demonstrated its efficacy in reversing memory impairment in animal models and exhibiting antidepressant-like properties, positioning it as a candidate for conditions such as Alzheimer's disease, depression, and other neurodegenerative disorders.